Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
22 août 2022 01h05 HE
|
Kinarus Therapeutic Holding AG
KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2...
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15 août 2022 16h05 HE
|
Icosavax, Inc.
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial...
Pfizer und BioNTech treiben COVID-19-Impfstoffstrategie weiter voran: neue klinische Studie mit Impfstoffkandidaten der nächsten Generation mit verbessertem Design des Spike-Proteins begonnen
27 juil. 2022 06h45 HE
|
BioNTech SE
NEW YORK und MAINZ, Deutschland, 27. Juli 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute den Beginn einer randomisierten, aktiv kontrollierten und...
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
27 juil. 2022 06h45 HE
|
BioNTech SE
NEW YORK and MAINZ, Germany, July 27, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind...
Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing
14 juil. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that...
Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVID
14 juil. 2022 07h00 HE
|
Panacea Life Sciences Holdings, Inc.
GOLDEN, Colo., July 14, 2022 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) (“Panacea” or the “Company”), a Colorado, USA-based cannabinoid research-focused company providing...
Pfizer und BioNTech schließen neue Liefervereinbarung mit der US-Regierung für zusätzliche Dosen des COVID-19-Impfstoffs
29 juin 2022 16h45 HE
|
BioNTech SE
Liefervereinbarung umfasst 105 Millionen 30 µg-, 10 µg- sowie 3 µg-Dosen, die bis einschließlich des vierten Quartals 2022 geliefert werden sollen; die US-Regierung hat die Option, 195 Millionen...
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
29 juin 2022 16h45 HE
|
BioNTech SE
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses NEW YORK and MAINZ, GERMANY, JUNE...
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
25 juin 2022 10h02 HE
|
BioNTech SE
Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels;...
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
21 juin 2022 16h01 HE
|
Aeterna Zentaris Inc
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...